X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (79) 79
oncology (70) 70
female (64) 64
aged (58) 58
middle aged (52) 52
index medicus (47) 47
male (47) 47
adult (46) 46
cancer (45) 45
chemotherapy (40) 40
antineoplastic combined chemotherapy protocols - therapeutic use (36) 36
treatment outcome (32) 32
prognosis (31) 31
aged, 80 and over (25) 25
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
cisplatin (21) 21
survival analysis (21) 21
care and treatment (18) 18
carcinoma (17) 17
cisplatin - administration & dosage (16) 16
further section · weitere sektionen (16) 16
research (16) 16
survival (16) 16
retrospective studies (15) 15
therapy (15) 15
bladder cancer (14) 14
metastasis (14) 14
antineoplastic agents (13) 13
article (13) 13
neoplasm metastasis (13) 13
antimitotic agents (12) 12
carboplatin (12) 12
chemotherapy, adjuvant (12) 12
human (12) 12
medicine & public health (12) 12
ovarian cancer (12) 12
urology & nephrology (12) 12
antineoplastic agents - therapeutic use (11) 11
antineoplastic combined chemotherapy protocols - administration & dosage (11) 11
gemcitabine (11) 11
neoplasm staging (11) 11
ovarian neoplasms - drug therapy (11) 11
survival rate (11) 11
cancer patients (10) 10
carcinoma, renal cell - drug therapy (10) 10
follow-up studies (10) 10
medical colleges (10) 10
ovarian neoplasms - pathology (10) 10
paclitaxel - administration & dosage (10) 10
phase-ii trial (10) 10
urologic neoplasms - drug therapy (10) 10
urology (10) 10
carboplatin - administration & dosage (9) 9
disease-free survival (9) 9
drug administration schedule (9) 9
drug therapy (9) 9
greece (9) 9
kidney neoplasms - drug therapy (9) 9
oncology, experimental (9) 9
paclitaxel (9) 9
patient outcomes (9) 9
phase-iii trial (9) 9
priority journal (9) 9
sunitinib (9) 9
surgery (9) 9
trial (9) 9
clinical trials (8) 8
cohort studies (8) 8
controlled study (8) 8
fluorouracil (8) 8
fluorouracil - administration & dosage (8) 8
hematology, oncology and palliative medicine (8) 8
immunohistochemistry (8) 8
interferon-alpha (8) 8
kaplan-meier estimate (8) 8
methotrexate (8) 8
transitional-cell carcinoma (8) 8
urinary bladder neoplasms - drug therapy (8) 8
urologic neoplasms - pathology (8) 8
urothelial cancer (8) 8
vinblastine (8) 8
analysis (7) 7
angiogenesis (7) 7
antineoplastic combined chemotherapy protocols (7) 7
bevacizumab (7) 7
cancer survival (7) 7
cisplatin - adverse effects (7) 7
colorectal cancer (7) 7
combination chemotherapy (7) 7
diagnosis (7) 7
gastric cancer (7) 7
leucovorin (7) 7
metastatic (7) 7
pharmacology & pharmacy (7) 7
prognostic-factors (7) 7
prospective studies (7) 7
radiotherapy (7) 7
randomized-trial (7) 7
risk factors (7) 7
transitional-cell-carcinoma (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2005, Volume 23, Issue 34, pp. 8580 - 8587
Journal Article
European Journal of Cancer Care, ISSN 0961-5423, 11/2015, Volume 24, Issue 6, pp. 768 - 770
Journal Article
Journal Article
Current Cancer Drug Targets, ISSN 1568-0096, 08/2008, Volume 8, Issue 5, pp. 349 - 358
Angiogenesis is an important factor for cancer development and progression in humans. Hereditary and sporadic renal cell carcinoma are characterized by... 
GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | INTERFERON-ALPHA | ONCOLOGY | DAYS ON/7 DAYS | RAF KINASE | TYROSINE KINASE INHIBITOR | RANDOMIZED-TRIAL | ANTITUMOR-ACTIVITY | FACTOR ANTIBODY | HYPOXIA-INDUCIBLE FACTORS
Journal Article
European Journal of Cancer, ISSN 0959-8049, 02/2020, Volume 126, pp. 125 - 135
Overexpression of c-Myc is commonly seen in human ovarian cancers, and this could be a potentially novel therapeutic target for this disease. JQ1, a selective... 
Ovarian | JQ1 | JAK/STAT | c-Myc | BRD4
Journal Article
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, ISSN 2212-4403, 2012, Volume 113, Issue 2, pp. 234 - 238
Journal Article
Journal Article
Journal Article
Oncology, ISSN 0030-2414, 01/2013, Volume 84, Issue 3, pp. 158 - 165
Objective: The prognosis for patients with platinum-resistant advanced ovarian cancer remains poor. The impact of approved agents on survival has not been... 
Clinical Study | Chemotherapy | Ovarian cancer | Platinum-resistant | PEGYLATED LIPOSOMAL DOXORUBICIN | CARBOPLATIN | AUSTRALIA | INTERGROUP TRIAL | CYCLOPHOSPHAMIDE | STAGE-III | GEMCITABINE | PHASE-III TRIAL | WOMEN | CISPLATIN | ONCOLOGY | Prognosis | Follow-Up Studies | Adenocarcinoma, Mucinous - pathology | Endometrial Neoplasms - mortality | Adenocarcinoma, Clear Cell - mortality | Humans | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Ovarian Neoplasms - mortality | Cystadenocarcinoma, Serous - pathology | Neoplasm Recurrence, Local - mortality | Cystadenocarcinoma, Serous - drug therapy | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Female | Adenocarcinoma, Mucinous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Survival Rate | Peritoneal Neoplasms - mortality | Adenocarcinoma, Mucinous - mortality | Fallopian Tube Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cystadenocarcinoma, Serous - mortality | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Adenocarcinoma, Clear Cell - pathology | Aged | Neoplasm Staging | Adenocarcinoma, Clear Cell - drug therapy | Drug Resistance, Neoplasm - drug effects | Drug resistance | Medical prognosis
Journal Article
Cancer Medicine, ISSN 2045-7634, 08/2014, Volume 3, Issue 4, pp. 835 - 844
Journal Article
Oncology, ISSN 0030-2414, 06/2008, Volume 73, Issue 5-6, pp. 290 - 297
Journal Article